logo
logo
Immuneering Corporation

Immuneering Corporation

NASDAQ•IMRX
CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2021-07-30
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
連絡先情報
245 Main Street, Second Floor, Cambridge, MA, 02142, United States
617-500-8080
immuneering.com
時価総額
$178.97M
PER (TTM)
-3.1
34.3
配当利回り
--
52週高値
$10.08
52週安値
$1.10
52週レンジ
43%
順位44Top 53.8%
3.7
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 3.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%
直近4四半期の推移

EPS

-$0.38-22.45%
直近4四半期の推移

フリーCF

-$11.98M-11.08%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Financing Bolsters Cash Position Net cash provided by financing activities reached $226.9M, increasing total cash equivalents to $227.6M as of September 30, 2025.
Atebimetinib Clinical Data Lead candidate atebimetinib showed 86% overall survival and 53% progression free survival in updated interim data.
R&D Spending Prioritization Nine-month Research and development expenses slightly decreased 0.9% to $32.8M, prioritizing atebimetinib development.
Equity Issuance Significant Class A common stock issued increased shares outstanding to 63.5M from 31.1M since December 31, 2024.

リスク要因

Clinical Stage Operations Company is clinical-stage oncology firm; has no approved products, making future success difficult to evaluate or predict.
Continued Operating Losses Incurred significant net losses for several years; expects recurring losses for foreseeable future, delaying profitability.
Substantial Capital Requirement Requires substantial additional capital to finance operations; inability to raise funds may force program delays or elimination.
Regulatory Approval Uncertainty FDA approval processes are lengthy, time-consuming, and inherently unpredictable regarding outcomes for product candidates.

見通し

Pivotal Trial Dosing Planned Expects to dose first patient in pivotal Phase 3 trial for atebimetinib combination by mid-2026, pending regulatory feedback.
Focus Resources on Lead Made strategic decision to pause internal advancement of IMM-6-415, focusing resources on atebimetinib development.
Cash Runway Extended Current cash and equivalents estimated sufficient to fund operating expenses and capital requirements into 2029.
Future Regulatory Feedback Anticipates receiving regulatory feedback on pivotal Phase 3 clinical trial plans in the fourth quarter of 2025.

同業比較

売上高 (TTM)

Arcturus Therapeutics Holdings Inc.ARCT
$92.04M
-35.4%
Enanta Pharmaceuticals, Inc.ENTA
$66.98M
+0.6%
Entrada Therapeutics, Inc.TRDA
$61.52M
-71.4%

粗利益率 (最新四半期)

Assembly Biosciences, Inc.ASMB
100.0%
+0.0pp
Sangamo Therapeutics, Inc.SGMO
100.0%
+0.0pp
Arcturus Therapeutics Holdings Inc.ARCT
80.5%
-19.5pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
SLS$511.37M-15.0-95.2%1.2%
TRDA$415.83M-4.4-26.4%12.7%
FHTX$325.13M-4.9105.5%11.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月19日
|
EPS:-$0.31
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月12日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.38-22.4%
    不明

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月13日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.40-14.9%
    不明

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月5日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.42-14.3%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月20日|
    売上高: $0.00+0.0%
    |
    EPS: $-2.04-8.5%
    不明

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月13日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.49+14.0%
    不明

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.47+9.3%
    不明

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.49-101.2%
    不明

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月1日|
    売上高: $0.00-100.0%
    |
    EPS: $-1.88-0.5%
    不明